TumorGen

TumorGen's technology targets metastatic cancer cell clusters (MCCC) in the early stages of metastasis, offering a multifunctional microfluidic platform that can uncover invisible drug targets, validate candidate drugs in preclinical in vitro studies, and reduce risks for future clinical trials. TumorGen is building support and an ecosystem to develop and validate its patented technology. Assembling the right team of leading clinical oncologists, cancer researchers, and biotechnology partners is crucial for success in this new therapeutic field.